More importantly, pharmaceutical targeting of SGK3 attenuated HFD-induced obesity in mice, and the role of SGK3 in regulating adipogenesis was conserved between humans and mice. The gene discussed is SGK3; the disease is obesity due to melanocortin 4 receptor deficiency.